drugset / Trial / NCT04447092
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, phase 2 study of Pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer
Timeline
- Start
- 2020-07-01
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Irinotecan | Small molecule | 140 mg/m2 | — |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | — |
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | — |
| Subject | Oxaliplatin | Small molecule | 65 mg/m2 | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | — |